Want to see HK:2509 full AI Analyst Report?
Total Valuation
Qyuns Therapeutics Co., Ltd. Class H has a market cap or net worth of HK$3.86B. The enterprise value is HK$2.78B.
Market CapHK$3.86B
Enterprise ValueHK$2.78B
Share Statistics
Qyuns Therapeutics Co., Ltd. Class H has 227,071,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding227,071,600
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Qyuns Therapeutics Co., Ltd. Class H’s return on equity (ROE) is 0.44 and return on invested capital (ROIC) is 25.02%.
Return on Equity (ROE)0.44
Return on Assets (ROA)0.19
Return on Invested Capital (ROIC)25.02%
Return on Capital Employed (ROCE)0.29
Revenue Per Employee2.33M
Profits Per Employee912.08K
Employee Count337
Asset Turnover0.49
Inventory Turnover3.19
Valuation Ratios
The current PE Ratio of Qyuns Therapeutics Co., Ltd. Class H is 6.0. Qyuns Therapeutics Co., Ltd. Class H’s PEG ratio is -0.06.
PE Ratio6.0
PS Ratio4.80
PB Ratio5.43
Price to FCF9.62
Price to Operating Cash Flow6.26
PEG Ratio-0.06
Income Statement
In the last 12 months, Qyuns Therapeutics Co., Ltd. Class H had revenue of 786.08M and earned 306.31M in profits. Earnings per share was 1.37.
Revenue786.08M
Gross Profit664.66M
Operating Income319.74M
Pretax Income299.42M
Net Income306.31M
EBITDA351.83M
Earnings Per Share (EPS)1.37
Cash Flow
In the last 12 months, operating cash flow was 519.90M and capital expenditures -8.97M, giving a free cash flow of 510.93M billion.
Operating Cash Flow519.90M
Free Cash Flow510.93M
Free Cash Flow per Share2.25
Dividends & Yields
Qyuns Therapeutics Co., Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.10
52-Week Price Change-36.99%
50-Day Moving Average16.87
200-Day Moving Average17.76
Relative Strength Index (RSI)51.84
Average Volume (3m)97.10K
Important Dates
Qyuns Therapeutics Co., Ltd. Class H upcoming earnings date is Mar 26, 2027, Before Open (Confirmed).
Last Earnings DateAug 19, 2026
Next Earnings DateMar 26, 2027
Ex-Dividend Date―
Financial Position
Qyuns Therapeutics Co., Ltd. Class H as a current ratio of 2.22, with Debt / Equity ratio of 79.73%
Current Ratio2.22
Quick Ratio2.14
Debt to Market Cap0.15
Net Debt to EBITDA-1.09
Interest Coverage Ratio14.81
Taxes
In the past 12 months, Qyuns Therapeutics Co., Ltd. Class H has paid 71.11K in taxes.
Income Tax71.11K
Effective Tax Rate<0.01
Enterprise Valuation
Qyuns Therapeutics Co., Ltd. Class H EV to EBITDA ratio is 9.64, with an EV/FCF ratio of 8.65.
EV to Sales4.31
EV to EBITDA9.64
EV to Free Cash Flow8.65
EV to Operating Cash Flow8.48
Balance Sheet
Qyuns Therapeutics Co., Ltd. Class H has HK$1.04B in cash and marketable securities with HK$686.50M in debt, giving a net cash position of HK$355.86M billion.
Cash & Marketable SecuritiesHK$1.04B
Total DebtHK$686.50M
Net CashHK$355.86M
Net Cash Per ShareHK$1.57
Tangible Book Value Per ShareHK$2.94
Margins
Gross margin is 88.64%, with operating margin of 40.68%, and net profit margin of 38.97%.
Gross Margin88.64%
Operating Margin40.68%
Pretax Margin38.09%
Net Profit Margin38.97%
EBITDA Margin44.76%
EBIT Margin40.68%
Analyst Forecast
The average price target for Qyuns Therapeutics Co., Ltd. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast230.35%
EPS Growth Forecast―